^
    Back
    Association details:
    Biomarker:EGFR L858R + FGF3 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Thorac Oncol
    Title:

    Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer

    Published date:
    10/26/2020
    Excerpt:
    ...cohort 1, LM patients were treated with osimertinib with CSF and plasma genotyping performed before the first dosing of osimertinib (baseline, n=45);...In patients with T790M-negative CSF, EGFR exon 21 L858R mutation, concurrent FGF3 alteration and over 1st line osimertinib showed shortened iPFS.
    DOI:
    10.1016/j.jtho.2020.10.008